Simple diet lessons from nurses cut heart risk in dialysis patients

NCT ID NCT07277530

Completed Disease control Sponsor: HASSAN 1st university Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a nurse-led nutritional education program could help hemodialysis patients in Morocco lower dangerously high potassium levels. Thirty adults with end-stage kidney disease received 12 weeks of dietary guidance on potassium, fluids, and salt. After the program, the share of patients with safe potassium levels rose from 36.7% to 46.7%, showing that nurse-led education can be a practical solution in settings without dietitians.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nutritional education intervention
What this could lead to: If successful, this simple, low-cost program could be adopted in other dialysis centers lacking dietitians to help patients manage potassium and reduce heart risks.
What could go wrong: This was a small, single-group study with only 30 participants and no control group, so results may not apply broadly. The improvement in potassium levels was modest, and quality of life did not change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE 5D are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure Hyperkalemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE 5D HEMODIALYSIS HYPERKALEMIA

Contacts and locations

Locations

Settat Hemodialysis Center,el borouj Hemodialysis Center, Al amal Hemodialysis Center

Settat, Settat, 26000, Morocco

More trials for these conditions

Other studies related to the condition(s) this trial covers.